PCVX — Vaxcyte, Inc.
Vaxcyte, Inc., a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine that is in Phase 1/2 clinical trials to treat invasive pneumococcal disease and pneumonia. The company also develops VAX-XP to protect against emerging strains and address antibiotic resistance; VAX-A1, a conjugate vaccine candidate designed to treat Group A Strep; and VAX-PG, a novel protein vaccine candidate targeting keystone pathogen responsible for periodontitis. The company was formerly known as SutroVax, Inc. and changed its name to Vaxcyte, Inc. in May 2020. Vaxcyte, Inc. was incorporated in 2013 and is headquartered in San Carlos, California.
Company profile
- Sector: Healthcare
- Industry: Biotechnology
- Country: US
- Exchange: NASDAQ
- Employees: 414
- Website: https://vaxcyte.com
Latest SEC filings for PCVX
- 424B5 — 2026-10-08
- 424B5 — 2026-10-08
- FWP — 2026-10-07
- 424B5 — 2026-10-06
- 424B5 — 2026-10-06
- 8-K — 2026-09-03
- SCHEDULE 13G/A — 2026-08-11
- SCHEDULE 13G/A — 2026-08-07
- SCHEDULE 13G/A — 2026-08-06
- 10-Q — 2026-08-05
Latest PCVX news
- — Wall Street Analysts Think Vaxcyte (PCVX) Could Surge 75.6%: Read This Before Placing a Bet (Zacks Investment Research)
- — Wall Street Analysts Think Vaxcyte (PCVX) Could Surge 75.6%: Read This Before Placing a Bet (zacks.com)
- — Vaxcyte (NASDAQ:PCVX) EVP Jim Wassil Sells 18,000 Shares of Company Stock
- — Vaxcyte prices $500M equity offering and $500M convertible notes (seekingalpha_market)
- — Vaxcyte Announces Pricing of Concurrent Public Offerings of Common Stock, Pre-Funded Warrants and Convertible Senior Notes (globenewswire.com)
- — Vaxcyte: 'Strong Buy' On VAX-31 Trial Win IPD VAX-31 And Additional Readouts 1st Half 2027 (seekingalpha.com)
- — Vaxcyte (NASDAQ:PCVX) Sees Large Volume Increase Following Analyst Upgrade
- — Vaxcyte’s VAX-31 Meets All Primary Endpoints in Pivotal Phase III OPUS-1 Trial (defenseworld.net)
- — Novavax (NVAX) Surges 20.1%: Is This an Indication of Further Gains? (Zacks Investment Research)
- — Vaxcyte's VAX-31 Meets All Primary Endpoints in Pivotal Phase III OPUS-1 Trial (marketbeat.com)
Educational tool only — not investment advice.